The GPS Mdx test is a 17-gene expression assay performed on prostate biopsy tissue that may identify signals of favorable vs unfavorable pathology.

HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy.* The results show significant ...

The latest stats on cancer death rates in the UK offer encouraging news – and further progress against the disease is within ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

An Anglesey man wants to know why it took so long for Betsi health chiefs to start treatment on his "aggressive cancer" - a ...

Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, today announced the launch of Ibex 4, its next-generation platform. Built on Ibex's clinic ...

This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...

This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." ...

BCUHB patient waited three times longer than he should have for prostate cancer treatment. Delays likely advanced his condition, ombudsman finds.

Delays in treating a patient with an aggressive form of prostate cancer more than likely contributed to his disease advancing ...